<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01660893</url>
  </required_header>
  <id_info>
    <org_study_id>SR 3-01</org_study_id>
    <nct_id>NCT01660893</nct_id>
  </id_info>
  <brief_title>Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth</brief_title>
  <official_title>A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Renatus, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Triligent International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Renatus, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and
      Placebo for inducing pulpal anesthesia of the maxillary teeth in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will employ a multi-center, randomized, double-blind, placebo-controlled,
      parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered
      intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary
      right second premolar to maxillary left second premolar) sufficient to allow completion of
      the Study Dental Procedure.

      A total of 140 subjects, randomized 2:2:1 (Kovacaine Mist:Tetracaine alone:Placebo) will be
      enrolled to achieve 125 completed subjects; a total of 50 Kovacaine Mist subjects, 50
      tetracaine alone subjects and 25 placebo subjects. Recruitment will be from diverse dental
      patient populations. At the two study sites, a balanced enrollment of 70 subjects each is
      planned to allow for a potential 10% drop-out rate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).</measure>
    <time_frame>at 15 minutes with a 3 minute window</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoral Soft-tissue Anesthesia (Yes/no)</measure>
    <time_frame>at 15 minutes with a 3 minute window</time_frame>
    <description>Number of patients who reported no pain when incisive papilla and greater palatine foramen soft-tissue was tested with a probe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Heart Rate Higher Than 125 Bpm</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Heart Rate Lower Than 50 Bpm</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</measure>
    <time_frame>at any time within 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure</measure>
    <time_frame>from baseline to 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Profile Over Time of Heart Rate</measure>
    <time_frame>from baseline to 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Sniff Test</measure>
    <time_frame>administered at approximately 24 hours after drug administration</time_frame>
    <description>The change from screening in the the distance from the nose (in centimeters) that a patient is able to detect the smell of an alcohol swab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Profile Over Time of Systolic Blood Pressure</measure>
    <time_frame>from baseline to 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Profile Over Time of Diastolic Blood Pressure</measure>
    <time_frame>from baseline to 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Maximum Change From Baseline in Heart Rate</measure>
    <time_frame>from baseline to 120 minutes following drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Kovacaine Mist, 3 sprays unilateral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracaine Only, 3 sprays unilateral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracaine HCl 3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 3 sprays unilateral</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine HCl 3% and oxymetazoline HCl 0.05%</intervention_name>
    <description>3 unilateral intranasal sprays per dose</description>
    <arm_group_label>Kovacaine Mist, 3 sprays unilateral</arm_group_label>
    <other_name>Kovacaine Mist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine HCl 3%</intervention_name>
    <description>3 unilateral intranasal sprays per dose</description>
    <arm_group_label>Tetracaine Only, 3 sprays unilateral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 unilateral intranasal sprays per dose</description>
    <arm_group_label>Placebo, 3 sprays unilateral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older.

          -  Need for an operative restorative dental procedure requiring local anesthesia for a
             single vital maxillary tooth (other than a maxillary first, second, or third molar)
             with no evidence of pulpal pathology.

          -  Normal lip, nose, eyelid, and cheek sensation.

          -  Able to understand and sign the study informed consent document, communicate with the
             investigators, and understand and comply with the requirements of the protocol.

          -  Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.

          -  Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.

          -  Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated
             diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.

        Exclusion Criteria:

          -  Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).

          -  Inadequately controlled active thyroid disease of any type.

          -  Frequent nose bleeds (â‰¥ 5 per month).

          -  Having received dental care requiring a local anesthetic within the last 24 hours.

          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local
             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).

          -  History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or
             sulfite preservatives.

          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.

          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females
             of child-bearing potential will be required to take a urine pregnancy test on the day
             of, but prior to, study drug administration to rule out pregnancy.)

          -  Having received any investigational drug and/or participation in any clinical trial
             within 30 days prior to study participation.

          -  Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other
             nasal or oral decongestant on the day of the study procedure.

          -  History of congenital or idiopathic methemoglobinemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A. Moore, DMD/PhD/MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family and Cosmetic Dentistry</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2012</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>August 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <disposition_first_submitted>May 15, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 8, 2015</disposition_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>operative</keyword>
  <keyword>dental procedure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Kovacaine Mist, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="P2">
          <title>Tetracaine Only, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="P3">
          <title>Placebo, 3 Sprays Unilateral</title>
          <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kovacaine Mist, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="B2">
          <title>Tetracaine Only, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="B3">
          <title>Placebo, 3 Sprays Unilateral</title>
          <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="10.22"/>
                    <measurement group_id="B2" value="33.3" spread="11.10"/>
                    <measurement group_id="B3" value="32.7" spread="9.85"/>
                    <measurement group_id="B4" value="32.4" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).</title>
        <time_frame>at 15 minutes with a 3 minute window</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoral Soft-tissue Anesthesia (Yes/no)</title>
        <description>Number of patients who reported no pain when incisive papilla and greater palatine foramen soft-tissue was tested with a probe</description>
        <time_frame>at 15 minutes with a 3 minute window</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoral Soft-tissue Anesthesia (Yes/no)</title>
          <description>Number of patients who reported no pain when incisive papilla and greater palatine foramen soft-tissue was tested with a probe</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incisive Papilla</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater Palatine Foramen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Heart Rate Higher Than 125 Bpm</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Rate Higher Than 125 Bpm</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Heart Rate Lower Than 50 Bpm</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Rate Lower Than 50 Bpm</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</title>
        <time_frame>at any time within 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure</title>
        <time_frame>from baseline to 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="6.05"/>
                    <measurement group_id="O2" value="3.5" spread="8.34"/>
                    <measurement group_id="O3" value="1.2" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="5.35"/>
                    <measurement group_id="O2" value="4.5" spread="4.12"/>
                    <measurement group_id="O3" value="6.2" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Profile Over Time of Heart Rate</title>
        <time_frame>from baseline to 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Profile Over Time of Heart Rate</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="9.07"/>
                    <measurement group_id="O2" value="69.1" spread="7.95"/>
                    <measurement group_id="O3" value="81.0" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="8.3"/>
                    <measurement group_id="O2" value="67.1" spread="7.03"/>
                    <measurement group_id="O3" value="75.8" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="9.48"/>
                    <measurement group_id="O2" value="64.5" spread="6.36"/>
                    <measurement group_id="O3" value="NA">Data was not collected as study dental procedure was still ongoing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="8.65"/>
                    <measurement group_id="O2" value="64.3" spread="5.70"/>
                    <measurement group_id="O3" value="73.8" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="11.34"/>
                    <measurement group_id="O2" value="65.3" spread="8.31"/>
                    <measurement group_id="O3" value="70.2" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="7.74"/>
                    <measurement group_id="O2" value="64.3" spread="8.39"/>
                    <measurement group_id="O3" value="72.0" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="6.31"/>
                    <measurement group_id="O2" value="65.0" spread="8.43"/>
                    <measurement group_id="O3" value="70.8" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Sniff Test</title>
        <description>The change from screening in the the distance from the nose (in centimeters) that a patient is able to detect the smell of an alcohol swab.</description>
        <time_frame>administered at approximately 24 hours after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Sniff Test</title>
          <description>The change from screening in the the distance from the nose (in centimeters) that a patient is able to detect the smell of an alcohol swab.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="5.44"/>
                    <measurement group_id="O2" value="0.8" spread="7.69"/>
                    <measurement group_id="O3" value="2.1" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Profile Over Time of Systolic Blood Pressure</title>
        <time_frame>from baseline to 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Profile Over Time of Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.0" spread="8.23"/>
                    <measurement group_id="O2" value="116.1" spread="11.0"/>
                    <measurement group_id="O3" value="125.5" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.5" spread="6.82"/>
                    <measurement group_id="O2" value="114.2" spread="5.51"/>
                    <measurement group_id="O3" value="118.8" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.0" spread="11.34"/>
                    <measurement group_id="O2" value="110.0" spread="4.24"/>
                    <measurement group_id="O3" value="NA">Data was not collected as study dental procedure was still ongoing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.5" spread="9.26"/>
                    <measurement group_id="O2" value="113.6" spread="9.31"/>
                    <measurement group_id="O3" value="118.8" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1" spread="9.68"/>
                    <measurement group_id="O2" value="113.3" spread="7.27"/>
                    <measurement group_id="O3" value="121.7" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.7" spread="8.34"/>
                    <measurement group_id="O2" value="112.0" spread="6.93"/>
                    <measurement group_id="O3" value="119.7" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.5" spread="10.89"/>
                    <measurement group_id="O2" value="113.7" spread="9.31"/>
                    <measurement group_id="O3" value="119.2" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Profile Over Time of Diastolic Blood Pressure</title>
        <time_frame>from baseline to 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Profile Over Time of Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="5.09"/>
                    <measurement group_id="O2" value="73.0" spread="7.09"/>
                    <measurement group_id="O3" value="77.7" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread="7.06"/>
                    <measurement group_id="O2" value="73.8" spread="5.65"/>
                    <measurement group_id="O3" value="75.5" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" spread="6.96"/>
                    <measurement group_id="O2" value="70.0" spread="1.41"/>
                    <measurement group_id="O3" value="NA">Data was not collected as study dental procedure was still ongoing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="5.8"/>
                    <measurement group_id="O2" value="72.2" spread="6.03"/>
                    <measurement group_id="O3" value="74.2" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="6.62"/>
                    <measurement group_id="O2" value="75.9" spread="6.52"/>
                    <measurement group_id="O3" value="77.8" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="8.78"/>
                    <measurement group_id="O2" value="73.1" spread="6.40"/>
                    <measurement group_id="O3" value="78.8" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" spread="10.91"/>
                    <measurement group_id="O2" value="72.1" spread="8.13"/>
                    <measurement group_id="O3" value="77.7" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Maximum Change From Baseline in Heart Rate</title>
        <time_frame>from baseline to 120 minutes following drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Mist, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O2">
            <title>Tetracaine Only, 3 Sprays Unilateral</title>
            <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo, 3 Sprays Unilateral</title>
            <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Maximum Change From Baseline in Heart Rate</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="8.62"/>
                    <measurement group_id="O2" value="3.5" spread="7.09"/>
                    <measurement group_id="O3" value="2.3" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kovacaine Mist, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Tetracaine HCl 3% and oxymetazoline HCl 0.05%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="E2">
          <title>Tetracaine Only, 3 Sprays Unilateral</title>
          <description>Tetracaine HCl 3%
Tetracaine HCl 3%: 3 unilateral intranasal sprays per dose</description>
        </group>
        <group group_id="E3">
          <title>Placebo, 3 Sprays Unilateral</title>
          <description>Placebo
Placebo: 3 unilateral intranasal sprays per dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <description>Tearing or watery eyes</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia eye</sub_title>
                <description>Numbness around eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaesthetic Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Abnormal taste</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Runny nose</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <description>Intranasal stinging or burning</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngeal Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intranasal Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sharon M. Gordon</name_or_title>
      <organization>University of Maryland</organization>
      <phone>410-706-1656</phone>
      <email>sgordon@dental.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

